About Index Trending news
Analyze
Top 50 Pricing
ImmunoPhotonics

ImmunoPhotonics

Work at ImmunoPhotonics? Add yourself to this profile

ImmunoPhotonics

Developing a novel immunotherapy inCVAX, a minimally invasive vaccine that intends to cause a systemic antitumor response to treat late-stage metastatic cancers

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding
Venture capital (Series A)
$1,800,000
Employees

Unknown size

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when ImmunoPhotonics makes some noise.